Q3 2022 Earnings Forecast for LogicBio Therapeutics, Inc. Issued By William Blair (NASDAQ:LOGC) – Defense World

LogicBio Therapeutics, Inc. (NASDAQ:LOGC Get Rating) Equities researchers at William Blair boosted their Q3 2022 earnings per share (EPS) estimates for shares of LogicBio Therapeutics in a report issued on Tuesday, August 16th. William Blair analyst R. Prasad now expects that the company will post earnings per share of ($0.20) for the quarter, up from their previous forecast of ($0.25). William Blair has a Outperform rating on the stock. The consensus estimate for LogicBio Therapeutics current full-year earnings is ($0.88) per share. William Blair also issued estimates for LogicBio Therapeutics Q4 2022 earnings at ($0.22) EPS, Q4 2022 earnings at ($0.22) EPS, FY2022 earnings at ($0.77) EPS, FY2022 earnings at ($0.77) EPS, Q1 2023 earnings at ($0.32) EPS, Q2 2023 earnings at ($0.32) EPS, Q2 2023 earnings at ($0.32) EPS, Q3 2023 earnings at ($0.33) EPS, Q4 2023 earnings at ($0.34) EPS, Q4 2023 earnings at ($0.34) EPS, FY2023 earnings at ($1.29) EPS and FY2023 earnings at ($1.29) EPS.

LogicBio Therapeutics stock opened at $0.40 on Thursday. The stock has a market cap of $13.18 million, a PE ratio of -0.43 and a beta of 1.60. The company has a quick ratio of 2.74, a current ratio of 2.26 and a debt-to-equity ratio of 0.17. The businesss 50-day moving average price is $0.43 and its two-hundred day moving average price is $0.55. LogicBio Therapeutics has a 12-month low of $0.34 and a 12-month high of $5.15.

A number of hedge funds and other institutional investors have recently made changes to their positions in LOGC. Blair William & Co. IL acquired a new position in shares of LogicBio Therapeutics in the fourth quarter worth approximately $51,000. Samlyn Capital LLC lifted its stake in LogicBio Therapeutics by 2.5% in the fourth quarter. Samlyn Capital LLC now owns 1,511,417 shares of the companys stock valued at $3,492,000 after buying an additional 37,309 shares during the period. Acadian Asset Management LLC acquired a new position in LogicBio Therapeutics in the first quarter valued at approximately $32,000. Renaissance Technologies LLC acquired a new position in LogicBio Therapeutics in the first quarter valued at approximately $312,000. Finally, Virtu Financial LLC increased its holdings in shares of LogicBio Therapeutics by 312.4% during the first quarter. Virtu Financial LLC now owns 71,475 shares of the companys stock valued at $49,000 after acquiring an additional 54,145 shares in the last quarter. 55.20% of the stock is owned by institutional investors and hedge funds.

(Get Rating)

LogicBio Therapeutics, Inc, a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues.

Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Read more here:
Q3 2022 Earnings Forecast for LogicBio Therapeutics, Inc. Issued By William Blair (NASDAQ:LOGC) - Defense World